Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based
This online activity features an expert panel discussion of noteworthy lung cancer data reported in 2016. These findings encompass the rapidly developing fields of targeted agents, liquid biopsies, and immunotherapy. The experts in this program also discuss how they have incorporated recent findings in the clinic.
CME Activity Table of Contents
- Module 1: EGFR/ALK and Liquid Biopsies
- Module 2: Other Oncogenic Drivers / Targeted Agents in Small-cell Lung Cancer
- Module 3: Immunotherapy
Requirements for Successful Completion
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals (HCPs) interested in the treatment of lung cancer may also participate.
At the conclusion of this activity, participants should be better prepared to:
- State the design of clinical trials that have utilized prognostic and predictive markers in the treatment of patients with advanced forms of lung cancer
- Discuss key findings from recent clinical trials conducted in the setting of advanced NSCLC
- Explain recent efficacy and safety results in the context of evolving treatment paradigms in the field and applicability to clinical practices
- Describe planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced NSCLC management
Faculty, Staff, and Planners' Disclosures
Benjamin P. Levy, MD
Assistant Professor, Johns Hopkins Medicine
Clinical Director, Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Hospital
Disclosure: Consultant: AstraZeneca, Celgene, BMS, Eli Lilly, Genentech, Merck and Pfizer
Alexander Drilon, MD
Clinical Director, Developmental Therapeutics Clinic
Assistant Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Honoraria: Ariad, AzstraZeneca, Loxo Oncology, Inc., Igynta, and Blueprint Medicines
Sarah B. Goldberg, MD, MPH
Assistant Professor of Medicine (Medical Oncology)
Yale School of Medicine
New Haven, CT
Disclosure: Grant/Research Support: AstraZeneca
The staff of Physicians' Education Resource®, LLC, has no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
CME Provider Contact Information
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)